IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Buys 40,535 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 40,535 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was acquired at an average cost of $1.45 per share, with a total value of $58,775.75. Following the transaction, the insider directly owned 1,098,858 shares in the company, valued at $1,593,344.10. This trade represents a 3.83% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

IRIDEX Trading Up 2.2%

IRIDEX stock opened at $0.90 on Friday. The firm has a market capitalization of $15.78 million, a P/E ratio of -4.49 and a beta of 0.67. IRIDEX Corporation has a twelve month low of $0.61 and a twelve month high of $1.65. The stock’s fifty day simple moving average is $0.73 and its 200-day simple moving average is $0.95.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. Sell-side analysts predict that IRIDEX Corporation will post -0.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $3.00.

Hedge Funds Weigh In On IRIDEX

A number of institutional investors and hedge funds have recently modified their holdings of IRIX. Bank of New York Mellon Corp acquired a new stake in IRIDEX in the second quarter valued at $29,000. Diversify Advisory Services LLC purchased a new position in shares of IRIDEX in the 2nd quarter valued at about $30,000. Diversify Wealth Management LLC purchased a new position in shares of IRIDEX in the 1st quarter valued at about $35,000. United Capital Financial Advisors LLC acquired a new stake in shares of IRIDEX during the 2nd quarter worth about $41,000. Finally, Thompson Davis & CO. Inc. raised its position in shares of IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 18,944 shares in the last quarter. Institutional investors and hedge funds own 20.10% of the company’s stock.

IRIDEX News Roundup

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.